Health, biotechnology and life-science startups in the United States can access substantial non-dilutive research and development funding through the NIH, CDC and FDA Parent Small Business Innovation Research Grant, officially listed as PA-27-100.

The Parent SBIR programme supports U.S. small businesses developing innovative products and technologies that align with the missions of participating National Institutes of Health institutes, the Centers for Disease Control and Prevention and the Food and Drug Administration.

Unlike venture capital, SBIR funding does not require founders to surrender company equity. The small business retains ownership while receiving federal support to prove feasibility and develop the technology towards commercialisation.

The September 2026 submission cycle has already passed. The next standard deadlines are January 5, 2027 and April 5, 2027, with applications due by 5:00pm local time of the applicant organisation. The current parent announcement expires April 6, 2027.

What Is the Parent SBIR Grant?

SBIR is part of America’s Seed Fund and helps eligible U.S. small businesses transform promising scientific discoveries into commercially valuable technologies.

The current Parent SBIR supports several application routes:

• Phase I;
• Phase II;
• Fast-Track;
• Direct to Phase II.

Phase I generally establishes technical merit and feasibility. Phase II supports more substantial research and development after feasibility has been demonstrated.

NIH’s Fast-Track mechanism lets applicants submit Phase I and Phase II together, potentially reducing the gap between the two stages. Direct to Phase II may be available to NIH applicants that have already demonstrated feasibility without receiving an SBIR or STTR Phase I award for the project.

How Much Funding Can Startups Receive?

The general SBA budget guidelines currently provide approximately $323,090 for Phase I and $2,153,927 for Phase II, but individual NIH institutes may approve larger budgets for qualifying projects and approved waiver topics.

Under PA-27-100, examples of institute-specific limits include:

• NCI: up to $700,000 Phase I and $2.5 million Phase II;
• NHLBI: up to $400,000 Phase I and $3 million Phase II;
• NIAID: up to $700,000 Phase I and $3 million Phase II;
• NINDS: up to $700,000 Phase I and $3 million Phase II;
• NIDDK: up to $400,000 Phase I and $2.5 million Phase II.

Applicants should not automatically request the maximum. NIH expects the proposed budget to be reasonable for the research.

Who Can Apply?

Only eligible United States small business concerns may apply.

The company must generally be organised for profit, operate primarily in the United States or make a significant contribution to the U.S. economy, and have no more than 500 employees including affiliates.

The current SBIR rules also permit some companies majority-owned by multiple qualifying venture-capital firms, private-equity firms or hedge funds, subject to detailed ownership requirements.

International companies cannot apply directly as foreign organisations.

For the SBIR mechanism, the small business should perform the majority of the research effort, and the principal investigator is generally expected to have primary employment with the small business.

What Types of Projects Can Be Funded?

The project must align with a participating agency’s mission.

Potential technologies include:

• Therapeutics and biologics;
• Medical devices;
• Diagnostics;
• Digital health products;
• AI-enabled health technologies;
• Clinical research tools;
• Vaccines;
• Research instrumentation;
• Health-data platforms;
• Disease monitoring technologies;
• Preventive-health innovations.

Applicants should determine which NIH institute is most closely aligned with their technology before applying.

How Are Applications Evaluated?

A strong SBIR application needs more than an interesting scientific idea.

Reviewers consider the importance of the problem, technical approach, feasibility, research team, resources and eventual commercial potential.

For Phase II and Fast-Track applications, the business and commercialisation plan becomes especially important.

Applicants should demonstrate who will ultimately buy the product, the regulatory pathway where relevant, competing technologies, intellectual-property position and the milestones required before commercial launch.

Start Your Registrations Early

Federal registrations can become one of the most overlooked parts of an SBIR application.

Applicants may need active registrations involving SAM.gov, a Unique Entity Identifier, the SBA Company Registry, Grants.gov and eRA Commons.

NIH warns that organisational registration can take six weeks or longer.

A founder planning for January 5 should therefore avoid waiting until December to begin registrations.

Next NIH Parent SBIR Deadlines

The remaining dates under PA-27-100 are:

January 5, 2027: scientific review around March 2027, advisory council around May and earliest start around July.

April 5, 2027: scientific review around July, council review around August and earliest start around December.

View the official NIH, CDC and FDA Parent SBIR opportunity PA-27-100

For science-driven U.S. startups, the Parent SBIR remains one of the most important sources of early-stage capital available without giving investors ownership in the company.